Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis.
Int J Parasitol Drugs Drug Resist
; 24: 100525, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38359731
ABSTRACT
Leishmaniasis is a disease caused by Leishmania spp., affecting millions of people around the world. For decades, its treatment has been based on pentavalent antimonials, which notoriously cause toxic side effects in patients. In this study, epoxy-α-lapachone incorporated into an oil-in-water-type microemulsion (ELAP-ME) and meglumine antimoniate (MA) were assayed in monotherapy and in combination (ELAP-ME/MA) in BALB/c mice infected with Leishmania (Leishmania) amazonensis. In general, there was a reduction in paw lesion size (up to 37% reduction) and decreases of parasite loads in the footpad (â¼40%) and lymph nodes (â¼31%) of animals treated with ELAP-ME/MA, when compared to the non-treated control groups. Analyses of serum biochemical parameters revealed that the ELAP-ME/MA showed lower renal and hepatic toxicity when compared to MA 2-doses/week monotherapy. These findings indicate that the ELAP-ME/MA combination may be a promising approach for the treatment of cutaneous leishmaniasis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Compuestos Organometálicos
/
Naftoquinonas
/
Leishmaniasis Cutánea
/
Leishmania
/
Antiprotozoarios
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Int J Parasitol Drugs Drug Resist
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Países Bajos